Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, announced that it had secured a new convertible note totaling $3 million. Financing for the note, which was comprised of three tranches, was led by Rapha Capital BioVentures Fund I, LP (“RCBVFI”). The company anticipates using the funds to support the clinical development of its lead product, the i/Blue(TM) Imaging System. According to the company, the proprietary system is poised to increase patient access to this important technology. In addition to the funding, Imagin Medical also named Kevin Slawin, MD, a leading uro oncologist and manager of RCBVFI, as a new board member. Slawin has cared for patients with cancer for more than 25 years and brings with him a deep knowledge of the field and of the needs of patients with prostate and bladder cancer. According to the announcement, Slawin noted that taking the lead investor role in Imagin signifies his appreciation of Imagin’s advanced technology and the potential it may bring to the improvement in the care of these patients. Finally the company also unveiled a new enhanced website, which features its new logo and reflects the change in energy and direction of Imagin Medical. “We are excited to bring Dr. Slawin onto the leadership team as a board member at Imagin Medical,” said Imagin Medical president and CEO Jim Hutchens in the press release. “This additional funding will support the company’s progress in bringing our lead product, the i/Blue(TM) Imaging System, through the FDA submission process over the next year.”
To view the full press release, visit https://nnw.fm/LCZew
About Imagin Medical
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://nnw.fm/IMEXF
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork